David Bridges
Elizabeth Holmes, the controversial founder of Theranos, is currently serving an 11-year prison sentence for defrauding investors through her scam-ridden blood testing startup. Her former partner, who shares two children with her, is now attempting to raise $50 million for a new blood testing venture. This move has raised eyebrows and sparked discussions about the future of medical diagnostics and health technology.
Initially, the internet’s reaction to this news was one of disbelief, with many believing it to be satirical or a hoax. However, this story is very real, as reported in the Tony pages of the New York Times. The new company, named Haemanthus—which also refers to a flower known as the blood lily—positions itself as “the future of diagnostics,” claiming to offer “a radically new approach to health testing.” This description closely mirrors the ambitious claims made by Theranos, raising questions about the viability of Evans’ venture.
You might find yourself pondering the motivations behind Billy Evans, who is characterized by the Times as an heir to a hotel fortune, choosing to delve into the blood testing industry. It’s worth considering that perhaps this direction aligns with the family’s business interests, or it could simply be a personal passion for innovation in healthcare. Whatever the reason, Evans’ foray into such a controversial field certainly invites scrutiny.
Stay Informed with Mashable Light Speed
According to reports from NPR, citing unnamed sources, Evans has successfully “raised millions” thus far, primarily from friends, family, and other supporters. The company appears to have a unique strategy by planning to initially conduct disease testing on pets before transitioning to human testing. This unconventional approach could be seen as a way to build credibility and experience in the field without risking human lives immediately.
The online community was quick to express their disbelief regarding this story. One user on Bluesky humorously clarified that the headline was indeed authentic, not a product of artificial intelligence or a joke. This reaction reflects the skepticism surrounding any new developments related to Theranos and its legacy.
The internet, as expected, has not held back on humor regarding Evans’ new venture. Many users have shared jokes and memes, reflecting the absurdity of the situation and the lingering shadow of Elizabeth Holmes over the world of health startups.
In an era filled with strange and unbelievable headlines, it is truly remarkable that the news continues to surprise and engage readers. The combination of health technology and the legacy of Theranos ensures that stories like this will remain in the public eye, prompting ongoing discussions about ethics, innovation, and the future of diagnostics.
var facebookPixelLoaded = false;
window.addEventListener(‘load’, function(){
document.addEventListener(‘scroll’, facebookPixelScript);
document.addEventListener(‘mousemove’, facebookPixelScript);
})
function facebookPixelScript() {
if (!facebookPixelLoaded) {
facebookPixelLoaded = true;
document.removeEventListener(‘scroll’, facebookPixelScript);
document.removeEventListener(‘mousemove’, facebookPixelScript);
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’//connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘1453039084979896’);
fbq(‘track’, “PageView”);
}
}
Brandon Fletcher
